



## Article

# Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease

Nicola Gambacorta <sup>1,†</sup>, Leonardo Caputo <sup>2,†</sup>, Laura Quintieri <sup>2,\*</sup>, Linda Monaci <sup>2</sup>, Fulvio Ciriaco <sup>3</sup>  
and Orazio Nicolotti <sup>1,\*</sup>

<sup>1</sup> Dipartimento di Farmacia Scienze del Farmaco, Università degli Studi di Bari “Aldo Moro”, Via E. Orabona, 4, I-70125 Bari, Italy; nicola.gambacorta1@uniba.it

<sup>2</sup> Institute of Sciences of Food Production, National Research Council of Italy, 70126 Bari, Italy; leonardo.caputo@ispa.cnr.it (L.C.); linda.monaci@ispa.cnr.it (L.M.)

<sup>3</sup> Dipartimento di Chimica, Università degli Studi di Bari “Aldo Moro”, Via E. Orabona, 4, I-70125 Bari, Italy; fulvio.ciriaco@uniba.it

\* Correspondence: laura.quintieri@ispa.cnr.it (L.Q.); orazio.nicolotti@uniba.it (O.N.)

† These authors contributed equally to this work.

**Abstract:** In the present work, and for the first time, three whey protein-derived peptides (IAEK, IPAVF, MHI), endowed with ACE inhibitory activity, were examined for their antiviral activity against the SARS-CoV-2 3C-like protease (3CL<sup>Pro</sup>) and Human Rhinovirus 3C protease (3C<sup>Pro</sup>) by employing molecular docking. Computational studies showed reliable binding poses within 3CL<sup>Pro</sup> for the three investigated small peptides, considering docking scores as well as the binding free energy values. Validation by in vitro experiments confirmed these results. In particular, IPAVF exhibited the highest inhibitory activity by returning an IC<sub>50</sub> equal to 1.21 μM; it was followed by IAEK, which registered an IC<sub>50</sub> of 154.40 μM, whereas MHI was less active with an IC<sub>50</sub> equal to 2700.62 μM. On the other hand, none of the assayed peptides registered inhibitory activity against 3C<sup>Pro</sup>. Based on these results, the herein presented small peptides are introduced as promising molecules to be exploited in the development of “target-specific antiviral” agents against SARS-CoV-2.

**Keywords:** antiviral peptides; protease inhibitors; molecular docking; rhinovirus; COVID-19; milk



**Citation:** Gambacorta, N.; Caputo, L.; Quintieri, L.; Monaci, L.; Ciriaco, F.; Nicolotti, O. Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. *Biomedicines* **2022**, *10*, 1067. <https://doi.org/10.3390/biomedicines10051067>

Academic Editor: Santiago Garcia-Vallve

Received: 6 March 2022

Accepted: 30 April 2022

Published: 4 May 2022

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

On 11 March 2020, the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic for the rapid spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) worldwide [1]. To date, the SARS-CoV-2 infection has caused more than 4 million deaths around the world [2].

The advent of effective vaccines and the adoption of restrictive prophylaxis measures, as well as appropriate sanitization procedures, have improved the global fight against SARS-CoV-2 [3]. However, the world still urgently needs new and affordable approaches to better counteract the spread of SARS-CoV-2 and prevent the spectrum of lethal adverse effects, especially in immunocompromised and vulnerable people. Thus, a wide range of therapies tackling the effects of COVID-19 in frail, symptomatic patients is increasingly gaining ground in clinical practice. They include both antivirals based on nucleotide analogs, such as Paxlovid™ (Nirmatrelvir and Ritonavir, Pfizer), Malnupirovir™ (Merck), Favipiravir, Remdesivir, and corticosteroids (such as Dexamethasone), and cytokine inhibitors (baricitinib and anti-IL-antibodies 6, anakinra). In addition, the use of monoclonal antibodies as an alternative to convalescent plasma is also spreading. Antivirals have been developed to block viral replication by inhibiting the RNA-dependent RNA replicase. Conversely, corticosteroids are used to avoid severe forms of the disease [4,5]. However, these drugs must be taken while under medical supervision or even in a clinical environment and they can often show serious adverse side effects. Furthermore, they all have a very

high cost, preventing their large-scale diffusion [4,6]. Thus, the discovery of new molecular entities, showing low toxicity and high specificity, to block the entry or replication of SARS-CoV-2 in host cells still represents a challenge regarding safer and more effective therapeutic solutions [7].

The SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CL<sup>pro</sup>), also named the main protease (M<sup>pro</sup>), which plays an important role in the virus's life cycle, is considered an attractive target for the discovery of promising antiviral agents [8]. Importantly, 3CL<sup>pro</sup> is involved in the replication process due to its two N-terminal domains, containing two  $\beta$ -barrel chymotrypsin-like folds ultimately responsible for the cleavage of the viral polyproteins to yield 16 mature non-structural proteins [9,10].

Human rhinoviruses (HRV, belonging to the Picornaviridae family), etiological agents of the common cold, also show a protease (HRV 3C protease or 3C<sup>pro</sup>) involved in the viral replication process. Briefly, 3C<sup>pro</sup> and 3CL<sup>pro</sup> are cysteine proteases and share a typical chymotrypsin-like folding, a nucleophilic cysteine residue in the active site, and a preference for a glutamine or glutamic acid residue in the primary binding residue (P1 site) of the substrate proteins. Picornaviral HRV 3C protease was studied in the recent past for its degree of homology with coronaviral 3C-like proteases (3CL<sup>pro</sup>) within the 3C coding region, including the strict conservation of the active-site residues, thus providing an additional rationale for targeting drug discovery efforts [11,12]. Nevertheless, subtle differences in the active-site structures of these proteases did not allow for the identification of common inhibitors [13]. Only recently, a duplex assay based on self-assembled monolayer desorption ionization (SAMDI)-MS analysis has been developed, allowing the identification of equipotent peptides against 3CL<sup>pro</sup> and HRV 3C<sup>pro</sup> [14].

Several studies have been carried out regarding the structural and functional characterization of these proteins, to be employed for high-throughput screening for the discovery of new effective inhibitors [15–17]. The search for 3CL<sup>pro</sup> inhibitors has been pursued by exploiting FDA-approved drugs, screening the libraries of natural and chemical compounds, and considering the de novo design of novel agents [18–20]. Based on these strategies, a number of putative inhibitors, whose structures can be grouped as peptidic and non-peptidic, have been identified and are awaiting further investigations before approval [16,21–23]. Recently, the 3CL<sup>pro</sup> covalent inhibitor Nirmatrelvir (PF-07321332, purchased in combination with Ritonavir) has been authorized for emergency use for COVID-19 patients not requiring supplemental oxygen [24,25].

In order to increase the affinity and efficacy, 3CL<sup>pro</sup> inhibitor substrates have been mainly modified by introducing some reactive chemical groups, such as Michael acceptors, aldehydes, epoxy ketones, and so on [8]. However, these structural changes promote the formation of covalent bonds with the catalytic cysteine responsible for the enzyme's irreversible inhibition and, thus, for potential toxicity [14,16].

Besides synthetic compounds, other studies on promising antiviral agents are focusing on the identification of bioactive molecules from natural sources [26–28]. Among others, health-promoting - represent an attractive option. It has been reported that the role of food ingredients and active components (i.e., bioactive peptides, polysaccharides, bioactive lipids, and natural polyphenols) in supporting immune function in the prevention and treatment of COVID-19 disease is important [29,30]. Noteworthy, several peptides from milk proteins showed their ability to inhibit the main SARS-CoV-2 proteases [30,31]. Natural peptides show lower toxicity and fewer side effects: their application in adjuvant therapies is also favored by their satisfactory biological activity profiles, in which antioxidant, antimicrobial, immunomodulatory, anti-inflammatory, and/or angiotensin-converting enzyme (ACE) inhibitory activities can coexist [26,32,33]. Interestingly, peptides taken from milk proteins and endowed with ACE inhibitory activity have also been investigated recently, via *in silico* studies, for their ability to prevent interaction among the COVID-19 spike glycoproteins and the host cell dipeptidyl peptidase-4 (DPP-4, [34]); however, these promising results are still lacking validation by *in vitro* or *in vivo* studies.

Recently, we investigated ACE inhibitory activity by peptide sequences, derived from the enzymatic hydrolysis of whey proteins and predicted by molecular docking and related prioritization studies. This approach allowed us to obtain three peptides—MHI, IAEK, and IPAVF—with ACE inhibitory  $IC_{50}$  values equal to or lower than  $25 \mu\text{M}$  [35]. Importantly, IPAVF and the related one-residue-longer sequence IPAVFK also exhibited DPP-4 inhibitory activity and antimicrobial activity against Gram-positive bacteria [33,34].

Building on these observations, we explored the potential of our recently studied ACE inhibitory peptides (i.e., MHI, IAEK, and IPAVF) in interfering with SARS-CoV2 3CL<sup>PRO</sup> functioning. With this in mind, we carried out an integrated theoretical and experimental investigation, involving first, molecular docking studies to rationally evaluate the putative chance of binding and then, *in vitro* testing for validation. Due to the occurrence of coinfection with a common virus (influenza viruses, human metapneumovirus, and seasonal coronaviruses) in SARS-CoV-2 positive specimens [36,37], peptides were also assayed for their ability to inhibit human rhinovirus 3C protease (EC: 3.4.22.28) in order to evaluate the peptides' exploitation as broad-spectrum antiviral agents.

## 2. Materials and Methods

### 2.1. Molecular Docking

SARS-CoV-2's main protease crystal structure was fetched from the Protein Data Bank by retrieving the entry 7L0D [38]. The protein was treated with the Protein Preparation Tool [39,40] available from Schrödinger Suite (New York, NY, USA). Such a method allows for optimizing the crystal structure by removing water molecules, adjusting the side-chain conformation, and adding the missing hydrogen atoms. The peptides to be docked were processed by employing the Ligprep Tool (Schrödinger, New York, NY, USA, for more information, see [41]) to generate all possible tautomers, as well as the protonation states at the physiological pH. The grid-box was generated so as to be suitable for standard precision (SP) peptide-docking protocol and, thus, was centered on the center of mass of the cognate ligand. Satisfactorily, Glide software (Schrödinger, New York, NY, USA) [42] could properly replicate the original binding pose of the co-crystallized molecule, returning a root mean square deviation (RMSD) value as small as  $1.025 \text{ \AA}$ .

The induced-fit docking protocol [43,44] was employed, using Glide with an OPLS3e force field [45] to analyze the binding mode of the selected ligands, together with conformational changes within the receptor. Such changes are not allowed in standard docking protocols. In detail, side-chain conformation predictions were performed on residues within  $6 \text{ \AA}$  from the ligand poses, together with the Glide SP redocking of each protein–ligand complex structure within  $30.0 \text{ kcal/mol}$  from the lowest energy.

The molecular mechanics/generalized born surface area (MM-GBSA, accessed on January 2022 [46]) method was employed in the last stage of the study for the computation of the binding free energies ( $\Delta G$ ) between the proteins and ligands. The Prime package (Schrödinger, LLC, New York, NY, USA) [47], available in the Schrödinger 2020-4 suite (New York, NY, USA), was used for this purpose.

For completeness, -additional molecular docking analyses were carried out against the HRV 3C protease by retrieving entry 2XYA [48] from the Protein Data Bank (<https://www.rcsb.org>, accessed on 10 January 2022) and are included in the Supplementary Information.

### 2.2. In Vitro Screening of the Antiviral Activity

Synthetic peptides were purchased (purity > 95%; GenScript, Leiden, The Netherlands) and resuspended in MQ water, then assayed at the concentrations of 2, 1, 1, 0.6 0.2 and 0.02 mg/mL (corresponding to 500 to  $5 \mu\text{M}$  for MHI, from 420 to  $4.2 \mu\text{M}$  for IPAVF, and from 366 to  $3.6 \mu\text{M}$  for IAEK). In the case of peptides with a value of relative inhibition (RI) percentage that was higher than 40–50% at the lowest assayed concentration, further dilutions were made.

### 2.2.1. SARS-CoV-2 3CL Protease Assay

The *in vitro* screening of enzyme inhibition activities was evaluated by using 3CL Protease, untagged (SARS-CoV-2 Assay Kit, Catalog #: 78042-1, BPS Bioscience, Inc., Allentown, PA, USA). According to the manufacturer's protocol, a fluorescent substrate, SARS-CoV-2 3CL Protease (GenBank Accession No. YP\_009725301, amino acids 1-306 (full-length), expressed in an *Escherichia coli* expression system, MW = 34 kDa) and a buffer composed of 20 mM Tris, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT, pH 7.3, was used for the inhibition assay. The protease inhibitor, GC376 MW 507.5 Da, with an IC<sub>50</sub> value of 0.017 μM was used as the positive control. Initially, 30 μL of diluted SARS-CoV-2 3CL protease, at the final concentration of 15 ng, was pipetted into a 96-well plate containing pre-pipetted 10 μL quantities of each test compound (final concentrations of each peptide ranged from 2 to 0.0002 mg/mL in the wells). The mixture was incubated at room temperature for 30 min with slow shaking. Afterward, the reaction was started by adding the substrate (10 μL), dissolved in the reaction buffer to 50 μL final volume, at a concentration of 40 μM, then the plates were incubated for 4 h at room temperature with slow shaking. The plates were sealed. Fluorescence intensity (Fi) was measured with the Varioskan microtiter plate-reader (Varioskan Flash, Thermo Fisher, Milan, Italy), exciting at a wavelength of 360 nm and detecting at a wavelength of 460 nm. Each sample was assayed in triplicate.

The percentage of relative inhibitions (RI %) was calculated as follows:

$$\% \text{ Relative Inhibition} \left( \begin{matrix} \% \\ RI \end{matrix} \right) = \left( \frac{FiC - FiT}{FiC} \right) \times 100$$

where C is the control and T is the test peptide or inhibitor.

### 2.2.2. HRV 3C Protease Determination Assay

The inhibition activity of synthetic peptides was assayed against human rhinovirus 3C protease (HRV 3C<sup>pro</sup>; EC:3.4.22.28), a cysteine protease that recognizes the cleavage site of Leu-Glu-Val-Leu-Phe-Gln\*Gly-Pro. Protease activity in the presence or absence of peptide inhibitors was determined colorimetrically, as reported, with an HRV 3C Protease Inhibitor Screening Kit (Catalog #: ab211089, Abcam, Cambridge, UK) according to the manufacturer's instructions. The kit also included a protease inhibitor as a positive control.

Briefly, the screening sample compound wells contained 10 μL of the test compounds at each concentration (final concentration/well from 1 to 0.05 mg/mL) or 10 μL of inhibitor, or 10 μL of assay buffer in the case of enzyme control, and 50 μL of enzyme solution. After the incubation of the plate at room temperature for 15 min, 40 μL of the substrate solution was added to each reaction, and absorbance (OD = 405 nm) was measured in a kinetic mode for 1–2 h at 37 °C on the Varioskan Flash microplate reader. Each sample was assayed in triplicate.

The percentage of relative inhibitions (RI) was calculated as follows:

$$\% \text{ Relative Inhibition} (\%RI) = \left( \frac{\text{slopeC} - \text{slopeT}}{\text{slopeC}} \right) \times 100$$

where C is the control and T is the test peptide or inhibitor.

### 2.3. Statistical Analyses

Results related to the 3CL protease inhibition percentage were subjected to a square root arcsin transformation in order to meet the homogeneity-of-variance assumptions, following Levene's test. The univariate general linear model (GLM) procedure, carrying out a two-way analysis of variance (ANOVA,  $p < 0.05$ ) using the IBM SPSS Statistics release 20 (IBM, Armonk, NY, USA) to evaluate the main and interaction effects of concentration levels and the assayed peptide types on the inhibition percentage of viral protease. Whenever required, the simple main effects of peptides and the assay control inhibitor on viral

protease inhibition percentage were also examined, applying a one-way ANOVA ( $p < 0.05$ ). Multiple comparisons among individual means for each assayed peptide and concentration level were performed using honestly significant difference (HSD) Tukey's test ( $p < 0.05$ ). A multiple regression test was run to predict the inhibition percentage of 3CL protease activity from different peptide concentrations.


The half-maximal inhibitory concentration ( $IC_{50}$ ) of peptides on SARS-CoV-2 3CL protease was calculated by using the software package SigmaPlot12 (Systat Software, Inc. SigmaPlot for Windows, San Jose, CA, USA) and referred to the micromolar range.

### 3. Results and Discussion

The chance of targeting SARS-CoV-2 main protease was rationally assessed by employing numerous structure-based approaches [49]. These studies were aimed at predicting the potential of the three small peptides (i.e., IAEK, IPAVF, and MHI) to act as antiviral inhibitors of SARS-CoV-2 main protease, as well as understanding the molecular interactions governing the recognition and the engagement of the binding site [50].

These sequences, endowed with high ACE inhibitor activity, were designed by the molecular pruning of longer  $\beta$ -lactoglobulin-derived peptides (e.g., IIAEKTIPAVF, and MHIRL); these latter were, in turn, purified and identified after the enzymatic hydrolysis of whey, for its transformation from a by-product of cheese manufacture to a high added-value compound [33]. The assumption that IAEK, IPAVF, and MHI could be good candidates for SARS-CoV-2 3CL<sup>pro</sup> inhibition was suggested by their sequences, which contain hydrophobic and aromatic amino acids that are able to interact with the hydrophobic regions of the 3CL<sup>pro</sup> active site, such as the S2 pocket [51]. In addition, bioactive peptides, such as ACE inhibitor ones, usually exhibit multifunctional properties that, once proved, make them excellent candidates for the development of multi-target drugs [33,34]. Similarly, this latter evidence has pushed other authors into investigating their activity as inhibitors of the SARS-CoV-2 main protease [52].

We preferred to use the induced fit docking protocol instead of the standard methods, the former being suited to exploring with higher accuracy and reliability the nature and the type of molecular interactions by considering both the ligand and binding site flexibility. In this respect, the effect of the induced fit on the key binding site residues (i.e., H41, N142, C145, H161, E166, and Q189) is assessed by computing the deviations from the crystallographic pose for each protein-oligopeptide complex; the following RMSD values, equal to 1.51 Å, 1.39 Å and 1.24 Å, are measured for IPAVF, IAEK, and MHI, respectively. Interestingly, we observed that Q189 and N142 are more sensitive to the induced fit, as these two residues experienced significant conformational changes, promoting a better fit and the easier accommodation of the three small peptides through the formation of cooperative hydrogen bonds. The N142  $\chi_1$  and Q189  $\chi_1$  and  $\chi_2$  torsional angle shifts, due to the induced fit, were reported in Table S1 of the Supplementary Information. Furthermore, the chance of interaction with the catalytic residue H41 and, in addition, with the key residue E166 is supposed to be crucial for the effective inhibition of the target [53,54]. As shown in Figure 1, the three peptides can form a network of hydrogen bonds within the binding pocket. Specifically, IPAVF can interact with the side chains of N142, H41, and Q189, and with the backbone of E166. Furthermore, its protonated nitrogen head can trigger an electrostatic interaction with the negatively charged side-chain of E166. As far as IAEK is concerned, hydrogen bonds with H41, N142, Q189, H163, and E166 were also detected, and the protonated arm of its terminal lysine residue can engage in electrostatic interaction with the side-chain of E166. Regarding MHI, the same hydrogen bonds with E166, N142, and Q189 were observed, and, notably,  $\pi$ - $\pi$  interactions with H41 through the imidazole ring of its histidine residue were also detected.



**Figure 1.** Panels (a–c) report the best pose returned from docking simulations for IPAVF (cyan sticks), IAEK (green sticks), and MHI (magenta sticks) peptides, respectively. Red arrows and green and blue lines depict hydrogen bonds,  $\pi$ - $\pi$ , and electrostatic interactions, respectively. Black wireframes show the original side-chain conformation of the 7L0D crystal structures. Yellow arrows highlight the shifting of the side chains from their original positions, due to the induced fit.

From an energetic point of view, we employed the OPLS3e force field to quantify the docking scores, and the MM-GBSA method to account for the binding of free energies. Interestingly, the values of the docking scores as well as of the binding free energies calculated for the three peptides were much better than those calculated for the reference X-ray-solved cognate ligand, ML188. For the sake of comparison, all the values are reported in Table 1.

**Table 1.** Values of the docking score and of MM-GBSA free energy of the best poses obtained through induced-fit docking.

	Docking Score (kcal/mol)	MM-GBSA (kcal/mol)
IPAVF	−10.967	−83.43
IAEK	−10.318	−76.24
MHI	−9.338	−78.80
ML188 cognate ligand	−5.283	−68.03

In addition, a more detailed analysis of the terms of the binding free energy function indicated that the Coulomb and van der Waal energy contributions were determinants for IPAVF, with values equal to −43.15 kcal/mol and −70.55 kcal/mol, respectively. On the other hand, the strongest hydrogen bonding contribution with a value of −6.13 kcal/mol was for IAEK, due to the presence of two charged side chains within its sequence.

Taken together, all the above-described results concerning the *in silico* investigations made us confident of the potential antiviral action of these natural small peptides in contrasting SARS-CoV-2 main protease, and this encouraged us to run experimental validations.

Recently, Behzadipour et al. [31] screened several di- and tri-peptides *in silico*, resulting from the simulated digestion of bovine milk proteins, for their SARS-CoV-2 M<sup>Pro</sup> inhibitory activity using molecular docking. Twenty peptides (with at least one aromatic-hydrophobic amino acid residue at the C-terminal side) showed the best binding energy but this was less than those obtained in the present work. In particular, three among these peptides, originating from the *in silico* proteolysis of  $\beta$ -caseins,  $\beta$ -lactoglobulin, and  $\alpha$ s2-casein, were able to form at least two hydrogen bonds and achieve  $\pi$ -alkyl hydrophobic interactions with the catalytic residues, C145 and H41, of SARS-CoV-2 M<sup>Pro</sup>, respectively. Other authors [32,34,55] have reported food-derived peptides with virtual 3CL<sup>Pro</sup> inhibitory activities, showing several potential advantages in terms of high binding affinity, bioavailability, and cost-effective synthesis.

In the past, a representative group of tripeptide aldehydes (CBZ-Leu-Phe-Gln-CHO) was prepared and analyzed to demonstrate poor inhibitory activity against 3C<sup>Pro</sup>. However, peptides that were modified with a primary amide (Gln- $\gamma$ -CONH<sub>2</sub>) were more active, revealing carbonyl oxygen–hydrogen bonds with the H161 and O $\gamma$  of T142 [56]. Our three

small peptides were also subjected to docking simulations within the binding site of 3C<sup>pro</sup> and similar interactions were experienced, although these yielded more disappointing scoring values. Additional details are available in the Supplementary Information.

Based on the theoretical analyses, the inhibitory activity of the three investigated peptides was experimentally evaluated against SARS-CoV-2 3CL<sup>pro</sup> and HRV 3C<sup>pro</sup>, both employing the catalytic dyad (His-Cys) for their functionality.

Satisfactory experimental results were observed, following the *in vitro* inhibition screening of the assayed peptides regarding SARS-CoV-2 3CL<sup>pro</sup> activity.

The half-maximal inhibitory concentrations (IC<sub>50</sub>) of the three assayed peptides against SARS-CoV-2 3CL<sup>pro</sup> were measured and are shown in Table 2, confirming IPAVF and IA EK as being more active than MHI; in particular, the IC<sub>50</sub> value of IPAVF was the best and was comparable with those obtained for the ACE inhibitor peptides against SARS-CoV-2 3CL<sup>pro</sup>, after *in silico* analyses [52]. The experimental data used to determine IC<sub>50</sub> are reported in Table S3 in the Supplementary Information.

**Table 2.** Experimental IC<sub>50</sub> values for the inhibition of SARS-CoV-2 3CL<sup>pro</sup>.

	IC <sub>50</sub> (μM)	95% Confidence Interval	
MHI	2700.62	1186.17	6145.84
IPAVF	1.21	0.02	9.53
IAEK	154.40	137.18	291.60
GC376 (inhibitor)	0.017	0.05	0.042

Similar inhibitory activities toward SARS-CoV2 in the μM range have been identified for synthetic tetrapeptides, pentapeptides, and octapeptides, as recently reviewed by Heydari et al. [57]. Moreover, the *in silico* hydrolysis of marine fish proteins by gastrointestinal enzymes released oligopeptides containing 1–3 aliphatic amino acids (A, L, V, I) with a high affinity toward SARS-CoV-2 3CL<sup>pro</sup>; some of these peptides were also predicted to play a role as dual binders toward SARS-CoV-2 3CL<sup>pro</sup> and monoamine oxidase A [58].

It is noteworthy that no appreciable activity was observed when testing the three small peptides against HRV 3C protease, the RI percentage being lower than a value of ca. 5% at a concentration of 1 mg/mL. A synoptic view is shown in Table 3. This finding is in agreement with our predictive docking studies. Interested readers can look at Figure S1 and Table S2 of the Supplementary Information for more details.

**Table 3.** The relative inhibition percentage (RI %) of HRV 3C protease by the assayed small peptides.

Peptides	Concentration for Well	Relative Inhibition (RI %)
MHI	250 μM	4.92 ± 1.02
IPAVF	210 μM	5.30 ± 1.06
IAEK	183 μM	4.54 ± 0.56

During the COVID-19 pandemic, several variants of SARS-CoV-2 emerged that, nevertheless, showed mutations in the binding domain of the spike protein receptor [59,60]. In all the variants of concern of the virus, no mutation in the M<sup>pro</sup> gene was recorded [61]. This suggests that any M<sup>pro</sup> inhibitor could also be effective against multiple variants of the same virus.

As already demonstrated for Nirmatrelvir [62], it is expected that the inhibitors studied in this work can block viral replication; therefore, they can also reduce infection. Nevertheless, unlike the currently authorized antivirals, the peptides studied could have very few or mild side effects and potentially have broad-spectrum applications. In particular, the peptides studied have been shown to have possible anti-hypertensive effects that would ameliorate the clinical conditions of COVID-19 patients. Finally, biologically active peptides would be cheaper and can be easily transformed into derivatives with improved pharmacological properties.

It is noteworthy that the three proposed peptides represent the minimum active sequences with the desired biological properties toward the SARS-CoV-2 3CL protease. This finding opens the way for the synthesis of peptides with improved activity. Their conversion into therapeutic peptides is, indeed, a further challenging task aimed firstly at tackling two intrinsic stumbling blocks: the low membrane permeability and the poor in vivo stability [63]. Inspired by consolidated medicinal chemistry strategies, backbone and side-chain modifications could be of great help. The former is normally pursued to improve the proteolytic stability of the peptides and includes, for instance, the replacement of L-amino acids with D-amino acids [64], the addition of methyl-amino acids [65], and the inclusion of  $\beta$ -amino acids [66] and peptoids [67]. The latter, instead, aims at exploring changes to improve the binding affinity and selectivity [68]. Together with these design approaches, targeted delivery strategies could also be exploited to overcome the inherent drawbacks of peptides [69]. These approaches could indeed be very valuable to obtain real therapeutic peptides; peptides with protease inhibitory activity have already been studied for various viruses, such as the Dengue virus, West Nile virus, and hepatitis C virus [57].

On the other hand, IAEK, IPAVF, and MHI are naturally included within whey proteins [33,35]; although their purification requires time and cost with a putative low yield, the fractionation of a mixture containing several inhibitory peptides may be an advantageous experimental design step toward the development of nutraceutical supplements with a more efficient manufacturing process and improved activity.

#### 4. Conclusions

In this work, the inhibitory activity of the whey-derived bioactive small peptides MHI, IAEK, and IPAVF against viral proteases was evaluated for the first time, indicating their possible role in blocking the replication processes of SARS-CoV-2.

Molecular docking studies predicted the relevant interactions between the peptides and key amino acid residues of the enzyme catalytic pocket of 3CL<sup>PRO</sup>. These results were validated by in vitro experiments that confirmed the highest antiviral activity for IPAVF and IAEK against 3CL<sup>PRO</sup>. These peptides of natural origin were previously obtained by the enzymatic hydrolysis of whey proteins and also displayed ACE inhibitory activity. It is noteworthy that their short sequences facilitate their synthesis as well as changes to their structure to improve stability and enhance activity. The results herein open the door to new opportunities for the development of dual-target small peptides that are endowed with antiviral 3CL<sup>PRO</sup> and inhibitory ACE activities.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/biomedicines10051067/s1>, Figure S1: Panels (a), (b), and (c) report the best pose returned from docking simulations for IPAVF (cyan sticks), IAEK (green sticks) and MHI (magenta sticks) peptides, respectively. Red arrows depict hydrogen bonds. Black wireframes show the original side-chain conformation of the 2XYA crystal structures of rhinovirus 3C protease. Table S1: Docking induced-fit variation of the torsional angles  $\chi_1$  for N142 and of  $\chi_1$  and  $\chi_2$  for Q189 from the X-ray structure (PDB\_ID: 7L0D) of SARS-CoV-2 3CL<sup>PRO</sup>. Table S2: Comparative docking score values for SARS-CoV-2 3CL<sup>PRO</sup> and HRV 3C<sup>PRO</sup>. Table S3: Relative inhibition percentage (RI %) of SARS-CoV-2 3CL<sup>PRO</sup> by the three small peptides assayed at different concentrations.

**Author Contributions:** Conceptualization, L.Q., O.N. and L.C.; methodology, L.Q., L.C., N.G., F.C., L.M. and O.N.; software, O.N., N.G. and F.C.; validation, L.Q., L.C. and N.G.; formal analysis, L.C., L.Q. and O.N.; investigation, L.C. and O.N.; resources, L.Q., L.M., N.G. and O.N.; data curation, L.Q., N.G., F.C. and O.N.; writing—original draft preparation, L.Q. and O.N.; writing—review and editing, L.Q., L.C. and O.N.; visualization, L.Q. and O.N.; supervision, L.Q. and O.N.; project administration, L.Q., L.C. and O.N.; funding acquisition, L.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the project ICONSS—Innovative Customer-Oriented Safe Solutions (ID 20431) within EIT Food 2020 program “COVID-19 Rapid Response Call for Innovation projects” and by the project “L’Evoluzione delle Produzioni Lattiero-Casearie: le Biotecnologie valorizzano la Tradizione”—ELEVATO, n. F/200112/03/X45, PON I&C 2014–2020.

**Institutional Review Board Statement:** The study did not require ethical approval.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy issues.

**Acknowledgments:** We are grateful to Pasquale Del Vecchio (CNR-ISPA, Bari, Italy) for data management support.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

## References

1. WHO. WHO Director-General's Opening Remarks at the Media Briefing on COVID-19—11 March 2020. World Health Organization (WHO): Geneva, Switzerland. 2020. Available online: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (accessed on 22 February 2022).
2. Karlinsky, A.; Kobak, D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. *eLife* **2021**, *10*, e69336. [[CrossRef](#)] [[PubMed](#)]
3. Bebenek, I.; Bannister, R.; Dubinion, J.; Fortin, M.; Liu, M.; Motter, A.L.; Rohde, C.M.; Wrzesinski, C. COVID-19 Therapeutics and Vaccines: A Race to Save Lives. *Toxicol. Sci.* **2022**, *185*, 119–127. [[CrossRef](#)] [[PubMed](#)]
4. Niknam, Z.; Jafari, A.; Golchin, A.; Danesh Pouya, F.; Nemati, M.; Rezaei-Tavirani, M.; Rasmi, Y. Potential therapeutic options for COVID-19: An update on current evidence. *Eur. J. Med. Res.* **2022**, *27*, 6. [[CrossRef](#)] [[PubMed](#)]
5. Tsai, S.C.; Lu, C.C.; Bau, D.T.; Chiu, Y.J.; Yen, Y.T.; Hsu, Y.M.; Fu, C.W.; Kuo, S.C.; Lo, Y.S.; Chiu, H.Y.; et al. Approaches towards fighting the COVID-19 pandemic. *Int. J. Mol. Med.* **2021**, *47*, 3–22. [[CrossRef](#)]
6. Chiu, M.N.; Bhardwaj, M.; Sah, S.P. Safety profile of COVID-19 drugs in a real clinical setting. *Eur. J. Clin. Pharmacol.* **2022**, *78*, 733–753. [[CrossRef](#)]
7. VanPatten, S.; He, M.; Altiti, A.; FCheng, K.; Ghanem, M.H.; Al-Abed, Y. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. *Future Med. Chem.* **2020**, *12*, 1647–1656. [[CrossRef](#)]
8. Liu, Y.; Liang, C.; Xin, L.; Ren, X.; Tian, L.; Ju, X.; Li, H.; Wang, Y.; Zhao, Q.; Liu, H.; et al. The development of Coronavirus 3C-Like protease (3CL<sup>PRO</sup>) inhibitors from 2010 to 2020. *Eur. J. Med. Chem.* **2020**, *206*, 112711. [[CrossRef](#)]
9. Needle, D.; Lountos, G.T.; Waugh, D.S. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2015**, *71*, 1102–1111. [[CrossRef](#)]
10. Moustaqil, M.; Ollivier, E.; Chiu, H.P.; Van Tol, S.; Rudolffi-Soto, P.; Stevens, C.; Bhumkar, A.; Hunter, D.J.B.; Freiberg, A.N.; Jacques, D.; et al. SARS-CoV-2 proteases PL<sup>PRO</sup> and 3CL<sup>PRO</sup> cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): Implications for disease presentation across species. *Emerg. Microbes Infect.* **2021**, *10*, 178–195. [[CrossRef](#)]
11. Adhikari, N.; Baidya, S.K.; Saha, A.; Jha, T. Structural insight into the viral 3C-like protease inhibitors: Comparative SAR/QSAR approaches. In *Viral Proteases and Their Inhibitors*; Academic Press: Cambridge, MA, USA, 2017; pp. 317–409.
12. Ng, C.S.; Stobart, C.C.; Luo, H. Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease? *Rev. Med. Virol.* **2021**, *31*, 1–22. [[CrossRef](#)]
13. Wang, H.M.; Liang, P.H. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors. *Expert Opin. Ther. Pat.* **2010**, *20*, 59–71. [[CrossRef](#)] [[PubMed](#)]
14. Liu, C.; Boland, S.; Scholle, M.D.; Bardiot, D.; Marchand, A.; Chaltin, P.; Blatt, L.M.; Beigelman, L.; Symons, J.A.; Raboisson, P.; et al. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. *Antivir. Res.* **2021**, *187*, 105020. [[CrossRef](#)] [[PubMed](#)]
15. Macchiagodena, M.; Pagliai, M.; Procacci, P. Identification of potential binders of the main protease 3CL<sup>PRO</sup> of the COVID-19 via structure-based ligand design and molecular modeling. *Chem. Phys. Lett.* **2020**, *750*, 137489. [[CrossRef](#)] [[PubMed](#)]
16. Chen, Y.W.; Yiu CP, B.; Wong, K.Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. *F1000Research* **2020**, *9*, 129. [[CrossRef](#)] [[PubMed](#)]
17. Kandeel, M.; Al-Nazawi, M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. *Life Sci.* **2020**, *251*, 117627. [[CrossRef](#)] [[PubMed](#)]
18. Alberga, D.; Gambacorta, N.; Trisciuzzi, D.; Ciriaco, F.; Amoroso, N.; Nicolotti, O. De Novo Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization. *J. Chem. Inf. Model* **2020**, *60*, 4582–4593. [[CrossRef](#)]
19. Ciriaco, F.; Gambacorta, N.; Alberga, D.; Nicolotti, O. Quantitative Polypharmacology Profiling Based on a Multifingerprint Similarity Predictive Approach. *J. Chem. Inf. Model* **2021**, *61*, 4868–4876. [[CrossRef](#)]
20. Alberga, D.; Trisciuzzi, D.; Montaruli, M.; Leonetti, F.; Mangiatordi, G.F.; Nicolotti, O. A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL). *J. Chem. Inf. Model* **2019**, *59*, 586–596. [[CrossRef](#)]

21. Pant, S.; Singh, M.; Ravichandiran, V.; Murty US, N.; Srivastava, H.K. Peptide-like and small-molecule inhibitors against Covid-19. *J. Biomol. Struct. Dyn.* **2021**, *39*, 2904–2913. [CrossRef]
22. Yang, H.; Yang, J. A review of the latest research on M<sup>Pro</sup> targeting SARS-COV inhibitors. *RSC Med. Chem.* **2021**, *12*, 1026–1036. [CrossRef]
23. Sabbah, D.A.; Hajjo, R.; Bardaweel, S.K.; Zhong, H.A. An Updated Review on SARS-CoV-2 Main Proteinase (M<sup>Pro</sup>): Protein Structure and Small-Molecule Inhibitors. *Curr. Top Med. Chem.* **2021**, *21*, 442–460. [CrossRef] [PubMed]
24. Pavan, M.; Bolcato, G.; Bassani, D.; Sturlese, M.; Moro, S. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. *J. Enzym. Inhib. Med. Chem.* **2021**, *36*, 1646–1650. [CrossRef] [PubMed]
25. EMA. EMA Receives Application for Conditional Marketing Authorisation Paxlovid (PF-07321332 and Ritonavir) for Treating Patients with COVID-19. European Medicines Agency (Amsterdam, The Netherlands). 2022. Available online: <https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-paxlovid-pf-07321332-ritonavir-treating> (accessed on 10 February 2022).
26. Pendyala, B.; Patras, A.; Dash, C. Phycobilins as Potent Food Bioactive Broad-Spectrum Inhibitors Against Proteases of SARS-CoV-2 and Other Coronaviruses: A Preliminary Study. *Front. Microbiol.* **2021**, *12*, 1399. [CrossRef] [PubMed]
27. Kato, F.; Nakatsu, Y.; Murano, K.; Wakata, A.; Kubota, T.; Hishiki, T.; Yamaji, T.; Kidokoro, M.; Katoh, H.; Takeda, M. Antiviral Activity of CD437 Against Mumps Virus. *Front. Microbiol.* **2021**, *12*, 751909. [CrossRef]
28. Sasidharan, S.; Selvaraj, C.; Singh, S.K.; Dubey, V.K.; Kumar, S.; Fialho, A.M.; Saudagar, P. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: Insights from molecular docking and molecular dynamics simulations. *J. Biomol. Struct. Dyn.* **2021**, *39*, 5706–5721. [CrossRef]
29. Galanakis, C.M.; Aldawoud, T.; Rizou, M.; Rowan, N.J.; Ibrahim, S.A. Food ingredients and active compounds against the coronavirus disease (COVID-19) pandemic: A comprehensive review. *Foods* **2020**, *9*, 1701. [CrossRef] [PubMed]
30. Hamid, H.; Thakur, A.; Thakur, N.S. Role of functional food components in COVID-19 pandemic: A review. *Ann. Phytomed. Int. J.* **2021**, *10*, S240–S250. [CrossRef]
31. Behzadipour, Y.; Gholampour, M.; Pirhadi, S.; Seradj, H.; Khoshneviszadeh, M.; Hemmati, S. Viral 3CL<sup>Pro</sup> as a target for antiviral intervention using milk-derived bioactive peptides. *Int. J. Pept. Res. Ther.* **2021**, *27*, 2703–2716. [CrossRef]
32. Pradeep, H.; Najma, U.; Aparna, H.S. Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2. *Protein J.* **2021**, *40*, 310–327. [CrossRef]
33. Brandelli, A.; Daroit, D.J.; Corrêa, A.P.F. Whey as a source of peptides with remarkable biological activities. *Food Res. Int.* **2015**, *73*, 149–161. [CrossRef]
34. Çakır, B.; Okuyan, B.; Şener, G.; Tunali-Akbay, T. Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis. *Eur. J. Pharmacol.* **2021**, *891*, 173781. [CrossRef] [PubMed]
35. Tondo, A.R.; Caputo, L.; Mangiatordi, G.F.; Monaci, L.; Lentini, G.; Logrieco, A.F.; Montaruli, M.; Nicolotti, O.; Quintieri, L. Structure-based identification and design of angiotensin converting enzyme-inhibitory peptides from whey proteins. *J. Agric. Food Chem.* **2019**, *68*, 541–548. [CrossRef] [PubMed]
36. Nowak, M.D.; Sordillo, E.M.; Gitman, M.R.; Mondolfi, A.E.P. Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus? *J. Med. Virol.* **2020**, *92*, 1699–1700. [CrossRef] [PubMed]
37. Dee, K.; Goldfarb, D.M.; Haney, J.; Amat, J.A.R.; Herder, V.; Stewart, M.; Szemiel, A.M.; Baguelin, M.; Murcia, P.R. Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: Implications for COVID-19 epidemiology. *J. Infect. Dis.* **2021**, *224*, 31–38. [CrossRef] [PubMed]
38. Lockbaum, G.J.; Reyes, A.C.; Lee, J.M.; Tilvawala, R.; Nalivaika, E.A.; Ali, A.; Kurt Yilmaz, N.; Thompson, P.R.; Schiffer, C.A. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. *Viruses* **2021**, *13*, 174. [CrossRef]
39. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments. *J. Comput. Aided. Mol. Des.* **2013**, *27*, 221–234. [CrossRef]
40. Schrödinger Release 2020-4: Protein Preparation Wizard; Epik, Schrödinger, LLC.: New York, NY, USA, 2016; Impact, Schrödinger, LLC.: New York, NY, USA, 2016; Prime, Schrödinger, LLC.: New York, NY, USA, 2020.
41. Schrödinger Release 2020-4: LigPrep; Schrödinger, LLC.: New York, NY, USA, 2020.
42. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. *J. Med. Chem.* **2004**, *47*, 1739–1749. [CrossRef]
43. Schrödinger Release 2020-4: Induced Fit Docking Protocol; Glide, Schrödinger, LLC.: New York, NY, USA, 2016; Prime, Schrödinger, LLC.: New York, NY, USA, 2020.
44. Sherman, W.; Day, T.; Jacobson, M.P.; Friesner, R.A.; Farid, R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. *J. Med. Chem.* **2006**, *49*, 534–553. [CrossRef]
45. Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J.Y.; Wang, L.; Lupyan, D.; Dahlgren, M.K.; Knight, J.L.; et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J. Chem. Theory Comput.* **2016**, *12*, 281–296. [CrossRef]
46. Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities. *Expert Opin. Drug Discov.* **2015**, *10*, 449–461. [CrossRef]

47. Schrödinger Release 2020-4; Prime, Schrödinger, LLC.: New York, NY, USA, 2020.
48. Baxter, A.; Chambers, M.; Edfeldt, F.; Edman, K.; Freeman, A.; Johansson, C.; King, S.; Morley, A.; Petersen, J.; Rawlins, P.; et al. Non-covalent inhibitors of rhinovirus 3C protease. *Bioorganic Med. Chem. Lett.* **2011**, *21*, 777–780. [[CrossRef](#)] [[PubMed](#)]
49. Piacentini, S.; La Frazia, S.; Riccio, A.; Pedersen, J.Z.; Topai, A.; Nicolotti, O.; Rossignol, J.F.; Santoro, M.G. Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: Role of glycoprotein-specific thiol oxidoreductase ERp57. *Sci. Rep.* **2018**, *8*, 10425. [[CrossRef](#)] [[PubMed](#)]
50. Trisciuzzi, D.; Siragusa, L.; Baroni, M.; Autiero, I.; Nicolotti, O.; Cruciani, G. Getting Insights into Structural and Energetic Properties of Reciprocal Peptide–Protein Interactions. *J. Chem. Inf. Model* **2022**, *62*, 1113–1125. [[CrossRef](#)] [[PubMed](#)]
51. Hernández González, J.E.; Eberle, R.J.; Willbold, D.; Coronado, M.A. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease. *Front. Mol. Biosci.* **2021**, *8*, 816166. [[CrossRef](#)]
52. Yathisha, U.G.; Srinivasa, M.G.; Siddappa Bc, R.; PMandal, S.; Dixit, S.R.; Pujar, G.V.; Bangera Sheshappa, M. Isolation and characterization of ACE-I inhibitory peptides from ribbonfish for a potential inhibitor of the main protease of SARS-CoV-2: An in silico analysis. *Proteins* **2022**, *90*, 982–992. [[CrossRef](#)]
53. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of M<sup>Pro</sup> from SARS-CoV-2 and Discovery of Its Inhibitors. *Nature* **2020**, *582*, 289–293. [[CrossRef](#)]
54. Huff, S.; Kummetha, I.R.; Tiwari, S.K.; Huante, M.B.; Clark, A.E.; Wang, S.; Bray, W.; Smith, D.; Carlin, A.F.; Endsley, M.; et al. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors. *J. Med. Chem.* **2022**, *65*, 2866–2879. [[CrossRef](#)]
55. Chourasia, R.; Padhi, S.; Chiring Phukon, L.; Abedin, M.M.; Singh, S.P.; Rai, A.K. A potential peptide from soy cheese produced using *Lactobacillus delbrueckii* WS4 for effective inhibition of SARS-CoV-2 main protease and S1 glycoprotein. *Front. Mol. Biosci.* **2020**, *7*, 601753. [[CrossRef](#)]
56. Webber, S.E.; Okano, K.; Little, T.L.; Reich, S.H.; Xin, Y.; Fuhrman, S.A.; Matthews, D.A.; Love, R.A.; Hendrickson, T.F.; Patick, A.K.; et al. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: Design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. *J. Med. Chem.* **1998**, *41*, 2786–2805. [[CrossRef](#)]
57. Heydari, H.; Golmohammadi, R.; Mirnejad, R.; Tebyanian, H.; Fasihi-Ramandi, M.; Moghaddam, M.M. Antiviral peptides against Coronaviridae family: A review. *Peptides* **2021**, *139*, 170526. [[CrossRef](#)]
58. Yao, Y.; Luo, Z.; Zhang, X. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients. *Food Funct.* **2020**, *11*, 5565–5572. [[CrossRef](#)] [[PubMed](#)]
59. Gupta, R.K. Will SARS-CoV-2 variants of concern affect the promise of vaccines? *Nat. Rev. Immunol.* **2021**, *21*, 340–341. [[CrossRef](#)] [[PubMed](#)]
60. Planas, D.; Veyer, D.; Baidaliuk, A.; Staropoli, I.; Guivel-Benhassine, F.; Rajah, M.M.; Planchais, C.; Porrot, F.; Robillard, N.; Puech, J.; et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **2021**, *596*, 276–280. [[CrossRef](#)] [[PubMed](#)]
61. Jukič, M.; Škrlič, B.; Tomšič, G.; Pleško, S.; Podlipnik, Č.; Bren, U. Prioritisation of compounds for 3CL<sup>Pro</sup> inhibitor development on SARS-CoV-2 variants. *Molecules* **2021**, *26*, 3003. [[CrossRef](#)]
62. Owen, D.R.; Allerton, C.M.N.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; et al. An oral SARS-CoV-2 M<sup>Pro</sup> inhibitor clinical candidate for the treatment of COVID-19. *Science* **2021**, *374*, 1586–1593. [[CrossRef](#)]
63. Wang, L.; Wang, N.; Zhang, W.; Cheng, X.; Yan, Z.; Shao, G.; Wang, X.; Wang, R.; Fu, C. Therapeutic peptides: Current applications and future directions. *Sig. Transduct. Target Ther.* **2022**, *7*, 48. [[CrossRef](#)]
64. Werner, H.M.; Cabaltea, C.C.; Horne, W.S. Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution. *Chembiochem* **2016**, *17*, 712–718. [[CrossRef](#)]
65. Chatterjee, J.; Rechenmacher, F.; Kessler, H. N-methylation of peptides and proteins: An important element for modulating biological functions. *Angew. Chem. Int. Ed. Engl.* **2013**, *52*, 254–269. [[CrossRef](#)]
66. Cheloha, R.W.; Watanabe, T.; Dean, T.; Gellman, S.H.; Gardella, T.J. Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. *ACS Chem. Biol.* **2016**, *11*, 2752–2762. [[CrossRef](#)]
67. Schneider, J.A.; Craven, T.W.; Kasper, A.C.; Yun, C.; Haugbro, M.; Briggs, E.M.; Svetlov, V.; Nudler, E.; Knaut, H.; Bonneau, R.; et al. Design of Peptoid-peptide Macrocycles to Inhibit the  $\beta$ -catenin TCF Interaction in Prostate Cancer. *Nat. Commun.* **2018**, *9*, 4396. [[CrossRef](#)]
68. Masri, E.; Ahsanullah Accorsi, M.; Rademann, J. Side-Chain Modification of Peptides Using a Phosphoranylidene Amino Acid. *Org. Lett.* **2020**, *22*, 2976–2980. [[CrossRef](#)] [[PubMed](#)]
69. Mitragotri, S.; Burke, P.A.; Langer, R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. *Nat. Rev. Drug Discov.* **2014**, *13*, 655–672. [[CrossRef](#)] [[PubMed](#)]